칼라 파마슈티컬스(KALA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.95 (+2.33%), 시가총액 $0.06B, 52주 범위 $0.08 ~ $19.63.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
칼라 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
칼라 파마슈티컬스의 현재 주가는 $0.95 (+2.33%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
칼라 파마슈티컬스의 시가총액은 약 $0.06B입니다.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candida